Recent News

• 11.26.2025 - Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
• 11.24.2025 - Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
• 11.20.2025 - Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
• 11.18.2025 - Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
• 09.15.2025 - Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson

Recent Filings

• 11.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.21.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.20.2025 - EX-99.1 EX-99.1
• 11.18.2025 - EX-99.1 EX-99.1
• 11.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.03.2025 - EX-99.1 EX-99.1